A Phase 3 interventional study of Best Available Therapy and Ruxolitinib in Polycythemia Vera, sponsored by Novartis Pharmaceuticals. Completed at 48 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-20.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing ruxolitinib in Polycythemia Vera — 5 open to participants now, 8 under way, 1 of them phase 3. ruxolitinib · Polycythemia Vera.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, this one is the 7th largest by enrollment, is one of 2 that started in 2014, is one of 5 in phase 3, and was the 7th registered.
279 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →5 of the 17 studies testing ruxolitinib in Polycythemia Vera are open now, in 3 countries. Recruiting first, the newest first:
Institute of Hematology & Blood Diseases Hospital, China · Sites in China
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18+
University of Washington · Sites in United States
Ages 18+
University of Birmingham · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 149 is above the median of 52 across 205 interventional studies indexed under Polycythemia Vera.
Median enrollment 110 across the 17 interventional studies. Of the 9 that completed or were terminated, 7 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 17 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
12 studies in Polycythemia Vera by Novartis: none open now, 2 under way, none of them phase 3. Of 7 finished, 3 (43%) have results posted.
Among the 12 studies in Polycythemia Vera by Novartis, this one is one of 2 that started in 2014, is one of 2 in phase 3, and was the 2nd registered.
Novartis’s Polycythemia Vera studies by the year they started, since 2013.
4 of the studies testing ruxolitinib in Polycythemia Vera that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT04644211Massachusetts General HospitalRuxolitinib in Thrombocythemia and Polycythemia Vera | 2027-07 |
| NCT04282187University of WashingtonDecitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms | 2027-11-11 |
Add all 4 to your calendar (.ics) → With an account.
Among the 17 studies testing ruxolitinib in Polycythemia Vera, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 12 in Polycythemia Vera:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study compared the efficacy and safety of ruxolitinib to Best Available Therapy (BAT) in patients with polycythemia vera (PV) who were hydroxyurea (HU) resistant or intolerant and did not have a palpable spleen.
This was a prospective, multi-center, open-label, randomized, Phase IIIb study evaluating efficacy and safety of ruxolitinib versus BAT as selected by the Investigator in patients with PV who are resistant to, or intolerant of HU.
The study comprised of the following periods:
Screening Period (up to 5 weeks: Day -35 to Day -1): Screening evaluations were performed at one or more clinic visits, and reviewed to determine eligibility before the patient was randomized in the study.
Core Treatment Period (Day 1 to Week 80):
Patients were randomized in 1:1 ratio to either treatment group (ruxolitinib or BAT) and were to be treated with their randomized treatment.
Crossover Treatment Period (Week 28 or after) for BAT patients only:
Patients randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib. Patients crossing over on or after Week 28 had to complete all assessments for the End of Treatment (EoT) visit of the Core Treatment Period followed by the assessments in Cross-over visit evaluation schedule.
Extended Treatment Period (Week 80 to Week 260):
Patients receiving ruxolitinib at Week 80 (including patients who have crossed over from BAT) were eligible to continue up to Week 260 in the Extended Treatment Period. Patients continued the ruxolitinib dose that they received at Week 80. Patients who received BAT at Week 80 were not eligible to enter the Extended Treatment Period and had to have the EoT visit at Week 80 and an End of study (EoS) visit 30 days after the EoT visit.
Follow-up Period:
Patients were followed for safety during 30 days after the last dose of study drug and EoS visit assessments were performed post 30 days after the last dose of study drug. Patients who completed EoT (Week 80 for patients who received BAT, Week 260 for patients who received ruxolitinib or from the time of premature discontinuation) were to be followed-up for every 3 months for survival till the end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Confirmed diagnosis of PV according to the 2008 World Health Organization criteria, Non-palpable spleen, Phlebotomy dependent, Resistant to or intolerant of hydroxyurea, performance status of 0, 1 or 2.
Exclusion Criteria:
Inadequate liver or renal function, Significant bacterial, fungal, parasitic, or viral infection requiring treatment, Active within the past 5 years, excluding specific skin cancers, Previously received treatment with a JAK inhibitor, Being treated with any agent, Women who are pregnant or nursing.
Other inclusion/exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
Drug: Ruxolitinib
Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
Drug: Best Available Therapy
Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
Also known as: BAT
Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
Also known as: INC424
Number of Participants Achieving Hematocrit (Hct) Control at Week 28
Proportion of patients achieving Hct control at Week 28 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8. Phlebotomy eligibility was defined by: * Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or * Confirmed Hct \> 48% The confirmation occurred 2 to 14 days subsequent to the initial observation.
Time frame: Week 28
Number of Participants Achieving a Complete Hematological Remission at Week 28
Proportion of patients achieving a complete hematological remission at Week 28 was defined by: * Hct control at Week 28 defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 28, and * Platelets ≤ 400 x 109/L at Week 28
Time frame: Week 28
Number of Participants Achieving a Hematocrit (Hct) Control at Week 52 and Week 80
Proportion of patients achieving a Hct control at Week 52 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52, and no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 - Endpoint for Week 80 was defined, similarly.
Time frame: Week 52 and 80
Number of Participants Achieving a Complete Hematological Remission at Week 52 and Week 80
Proportion of patients achieving a complete hematological remission at Week 52, was defined by: * Hct control at Week 52, as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * White Blood Count (WBC) \< 10 x10\^9/L at Week 52, and * Platelets ≤ 400 x 10\^9/L at Week 52 * Endpoint for Week 80 was defined, similarly.
Time frame: Week 52 and 80
Number of Participants With Phlebotomies Over Time
Phlebotomy eligibility was defined by Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.
Time frame: Baseline to Week 260
Change From Baseline in Hematocrit (Hct) at Each Visit
Hematocrit is the volume percentage of red blood cells (RBC) in the blood.
Time frame: Baseline, Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260
Change From Baseline in Hematocrit (Hct) at Each Scheduled Visit After Crossover in Participants Randomized to BAT Who Cross Over to Ruxolitinib
Hematocrit is the percentage of red blood cells (RBC) in the blood.
Time frame: Baseline (last assessment before cross over), Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 64, 76, 89, 102, 115, 128, 141, 154, 167, 180, 193, 206, 219 and 232 after cross-over
Spleen Length by Visit
Spleen length was assessed by manual palpation at every study visit.
Time frame: Week 4, 8, 12, 16, 20, 24, 28, 40, 52, 66, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234, 247 and 260
Change From Baseline in Eastern Cooperative Oncology Group (ECOG) Performance Status to Week 28
The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).
Time frame: Baseline and Week 28
Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28
Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: * Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score reduction of greater than or equal to 10 points from baseline to Week 28, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 28, and * Platelets ≤ 400 x 10\^9/L at Week 28, and * No palpable spleen at Week 28, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).
Time frame: Week 28
Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 52 and Week 80
Proportion of patients who achieved partial remission at Week 52 based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 52 and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 52 and * Platelets ≤ 400 x 109/L at Week 52 and * No palpable spleen at Week 52 and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria). * Endpoint for Week 80 was defined, similarly.
Time frame: Week 52 and 80
Number of Participants Achieving a Hematocrit (Hct) Control at Week 104, Week 156, Week 208 and Week 260.
Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.
Time frame: From Week 8 to Week 104, 156, 208 and 260
Number of Participants Achieving a Complete Hematological Remission at Week 104, Week 156, Week 208 and Week 260
Proportion of patients achieving a complete hematological remission at Week 104 as defined by Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.
Time frame: From Week 8 to Week 104, 156, 208 and 260
Number of Participants Who Achieved Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 104, Week 156, Week 208 and Week 260.
Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104, and * No palpable spleen at Week 104, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.
Time frame: From Week 8 to Week 104, 156, 208 and 260
Number of Participants With Transformation Free Survival Events
Transformation-free survival is defined as one of the following: 1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or 2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks. 3. Death due to any cause during treatment period
Time frame: Week 260 (ruxolitinib arm) and Week 80 (BAT arm)
Number of Participants With Overall Survival (OS) Events
Overall survival (OS) event is defined as death due to any cause. OS events were counted in the BAT arm, irrespective of whether participants crossed over to receive ruxolitinib when the event occurred.
Time frame: up to Week 260
Change From Baseline in Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.
Time frame: Baseline, Week 4, 8, 16, 28, 40, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247
Change From Baseline in Total Scores of MPN-SAF by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.
Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over
Change From Baseline in Score as Per European Quality of Life 5-Dimension 5-level (EQ-5D-5L) Questionnaire
EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.
Time frame: Baseline, Week 4, 8, 16, 28, 52, 80, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247
Change From Baseline in EQ-5D-5L VAS, by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.
Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 52, 92, 104, 117, 130, 143, 156, 169, 182, 195, 208, 221, 234 and 247 after cross-over
Change From Baseline in Work Productivity and Activity Impairment (WPAI) Questionnaire
The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10
Time frame: Baseline, Week 4, 8, 16, 28, 52 and 80
Change From Baseline in Work Productivity and Activity Impairment Questionnaire (WPAI), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10
Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28 and 52 after cross-over
Patient Global Impression of Change (PGIC)
The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.
Time frame: Week 4, 8, 16, 28, 40, 52 and 80
Summary of Patient Global Impression of Change (PGIC), by Visit in Patients From BAT Group Who Cross Over to Ruxolitinib After Crossover
The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.
Time frame: Baseline (last assessment before cross over), Week 4, 8, 16, 24, 28, 40, and 52 after cross-over
Number of Participants Developing Thrombosis
Proportion of participants developing any arterial or venous thromboembolic event
Time frame: From randomization to Week 80 for BAT and Week 260 for Ruxolitinib
Participants were randomized in 48 centers across 12 countries: Australia (1), Belgium (2), Canada (1), France (7), Germany (9), Hungary (3), India (2), Israel (3), Italy (7), South Korea (2), Spain (9) and Turkey (2)
| Milestone | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Started | 74 | 75 |
| Full analysis set | 74 | 75 |
| Crossover set | 0 | 58 |
| Completed | 59 | 61 |
| Not completed | 15 | 14 |
| Withdrew: Adverse event | 7 | 7 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Disease progression | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 2 | 1 |
| Withdrew: Subject/guardian decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 3 | 1 |
| Milestone | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Started | 0 | 58 |
| Completed | 0 | 38 |
| Not completed | 0 | 20 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Adverse event | 0 | 9 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Disease progression | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
Proportion of patients achieving Hct control at Week 28 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8. Phlebotomy eligibility was defined by: * Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or * Confirmed Hct \> 48% The confirmation occurred 2 to 14 days subsequent to the initial observation.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants Achieving Hematocrit (Hct) Control at Week 28 | 46 | 14 |
Proportion of patients achieving a complete hematological remission at Week 28 was defined by: * Hct control at Week 28 defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 28, and * Platelets ≤ 400 x 109/L at Week 28
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants Achieving a Complete Hematological Remission at Week 28 | 17 | 4 |
Proportion of patients achieving a Hct control at Week 52 was defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52, and no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 - Endpoint for Week 80 was defined, similarly.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 52 | 44 | 5 |
| Week 80 | 35 | 2 |
Proportion of patients achieving a complete hematological remission at Week 52, was defined by: * Hct control at Week 52, as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * White Blood Count (WBC) \< 10 x10\^9/L at Week 52, and * Platelets ≤ 400 x 10\^9/L at Week 52 * Endpoint for Week 80 was defined, similarly.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 52 | 17 | 3 |
| Week 80 | 18 | 2 |
Phlebotomy eligibility was defined by Confirmed Hct \> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Phlebotomy frequency: >0 - <=2 | 12 | 29 |
| Phlebotomy frequency: >2 - <=4 | 7 | 17 |
| Phlebotomy frequency: >4 - <=6 | 4 | 2 |
| Phlebotomy frequency: >6 - <=8 | 0 | 1 |
Hematocrit is the volume percentage of red blood cells (RBC) in the blood.
| volume percentage of RBC in blood | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 4 | -0.65 ± 2.943 | 1.25 ± 2.994 |
| Week 8 | -1.22 ± 3.634 | 1.63 ± 3.344 |
| Week 12 | -2.33 ± 4.581 | 1.70 ± 3.485 |
| Week 16 | -3.25 ± 4.179 | 1.83 ± 3.439 |
| Week 20 | -3.05 ± 4.307 | 1.45 ± 3.984 |
| Week 24 | -2.85 ± 4.094 | 1.52 ± 2.934 |
| Week 28 | -2.60 ± 4.101 | 2.09 ± 3.852 |
| Week 40 | -2.77 ± 4.538 | 2.05 ± 4.587 |
| Week 52 | -2.49 ± 4.445 | 1.68 ± 4.854 |
| Week 66 | -3.06 ± 4.573 | 2.73 ± 2.922 |
| Week 80 | -3.20 ± 3.886 | 0.62 ± 4.436 |
| Week 92 | -2.91 ± 4.203 | — |
| Week 104 | -3.19 ± 4.314 | — |
| Week 117 | -2.86 ± 4.540 | — |
| Week 130 | -3.13 ± 4.263 | — |
| Week 143 | -3.50 ± 3.463 | — |
| Week 156 | -3.54 ± 4.005 | — |
| Week 169 | -3.57 ± 4.477 | — |
| Week 182 | -2.94 ± 4.428 | — |
| Week 195 | -3.36 ± 4.515 | — |
| Week 208 | -3.23 ± 4.150 | — |
| Week 221 | -3.55 ± 4.413 | — |
| Week 234 | -3.31 ± 4.621 | — |
| Week 247 | -3.45 ± 4.053 | — |
| Week 260 | -2.93 ± 3.799 | — |
Hematocrit is the percentage of red blood cells (RBC) in the blood.
| Volume percentage of RBC in blood | All Crossover Patients |
|---|---|
| Week +4 | -2.44 ± 3.394 |
| Week +8 | -4.24 ± 5.322 |
| Week +12 | -5.73 ± 6.597 |
| Week +16 | -6.27 ± 7.101 |
| Week +20 | -5.76 ± 6.563 |
| Week +24 | -5.29 ± 6.518 |
| Week +28 | -6.04 ± 5.825 |
| Week +40 | -6.06 ± 6.301 |
| Week +52 | -5.91 ± 6.399 |
| Week +64 | -7.06 ± 6.051 |
| Week +76 | -6.16 ± 6.247 |
| Week +89 | -6.79 ± 6.046 |
| Week +102 | -6.21 ± 6.599 |
| Week +115 | -7.04 ± 6.103 |
| Week +128 | -7.41 ± 6.812 |
| Week +141 | -7.00 ± 6.310 |
| Week +154 | -7.06 ± 7.000 |
| Week +167 | -7.44 ± 7.426 |
| Week +180 | -7.51 ± 7.298 |
| Week +193 | -7.16 ± 5.331 |
| Week +206 | -7.09 ± 5.742 |
| Week +219 | -6.95 ± 5.936 |
| Week +232 | -7.51 ± 5.880 |
Spleen length was assessed by manual palpation at every study visit.
| cm | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 4 | 0.00 ± 0.000 | 0.04 ± 0.351 |
| Week 8 | 0.00 ± 0.000 | 0.01 ± 0.119 |
| Week 12 | 0.00 ± 0.000 | 0.01 ± 0.120 |
| Week 16 | 0.00 ± 0.000 | 0.23 ± 1.010 |
| Week 20 | 0.00 ± 0.000 | 0.13 ± 0.716 |
| Week 24 | 0.00 ± 0.000 | 0.09 ± 0.555 |
| Week 28 | 0.00 ± 0.000 | 0.20 ± 0.909 |
| Week 40 | 0.01 ± 0.120 | 0.52 ± 1.473 |
| Week 52 | 0.06 ± 0.482 | 0.07 ± 0.258 |
| Week 66 | 0.00 ± 0.000 | 0.00 ± 0.000 |
| Week 80 | 0.03 ± 0.246 | 0.00 ± 0.000 |
| Week 92 | 0.00 ± 0.000 | — |
| Week 104 | 0.05 ± 0.378 | — |
| Week 117 | 0.12 ± 0.985 | — |
| Week 130 | 0.18 ± 1.162 | — |
| Week 143 | 0.08 ± 0.458 | — |
| Week 156 | 0.05 ± 0.372 | — |
| Week 169 | 0.05 ± 0.378 | — |
| Week 182 | 0.05 ± 0.381 | — |
| Week 195 | 0.00 ± 0.000 | — |
| Week 208 | 0.00 ± 0.000 | — |
| Week 221 | 0.02 ± 0.129 | — |
| Week 234 | 0.00 ± 0.000 | — |
| Week 247 | 0.02 ± 0.136 | — |
| Week 260 | 0.10 ± 0.617 | — |
The ECOG scale of performance status described the level of functioning of participants in terms of their ability to care for themselves, daily activity, and physical ability. The ECOG performance was recorded as per ECOG performance status grades ranging from 0 (fully active, able to carry on all pre-disease performance without restriction) to 5 (dead).
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Grade 0 at baseline — 0: Fully active, able to carry on all pre-disease performance without restriction | 49 | 17 |
| Grade 0 at baseline — 1: Restricted in physically strenuous activity and able to carry out light or sedentary work | 2 | 1 |
| Grade 0 at baseline — 2: Ambulatory and capable of all self-care but unable to carry out any work activities | 0 | 0 |
| Grade 0 at baseline — 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours | 0 | 0 |
| Grade 0 at baseline — 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair | 0 | 0 |
| Grade 0 at baseline — Missing | 2 | 38 |
| Grade 1 at baseline — 0: Fully active, able to carry on all pre-disease performance without restriction | 9 | 1 |
| Grade 1 at baseline — 1: Restricted in physically strenuous activity and able to carry out light or sedentary work | 10 | 5 |
| Grade 1 at baseline — 2: Ambulatory and capable of all self-care but unable to carry out any work activities | 1 | 0 |
| Grade 1 at baseline — 3: Capable of only limited self-care, confined to bed or chair more than 50% of waking hours | 0 | 0 |
| Grade 1 at baseline — 4: Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair | 0 | 0 |
| Grade 1 at baseline — Missing | 1 | 13 |
Proportion of patients achieving a partial remission at Week 28, based on the ELN and IWG-MRT criteria, as defined by: * Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) score reduction of greater than or equal to 10 points from baseline to Week 28, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 28, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 28, and * Platelets ≤ 400 x 10\^9/L at Week 28, and * No palpable spleen at Week 28, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria).
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants Achieving a Partial Remission Based on the European Leukemia Net (ELN) and International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) Criteria at Week 28 | 7 | 0 |
Proportion of patients who achieved partial remission at Week 52 based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 52 and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 52 with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x109/L at Week 52 and * Platelets ≤ 400 x 109/L at Week 52 and * No palpable spleen at Week 52 and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria). * Endpoint for Week 80 was defined, similarly.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 52 | 5 | 0 |
| Week 80 | 4 | 0 |
Proportion of patients achieving a Hct control at Week 104 as defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104 and with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.
| Participants | Ruxolitinib |
|---|---|
| Week 104 — HU Resistant | 9 |
| Week 104 — HU Intolerant | 25 |
| Week 156 — HU Resistant | 9 |
| Week 156 — HU Intolerant | 21 |
| Week 208 — HU Resistant | 7 |
| Week 208 — HU Intolerant | 18 |
| Week 260 — HU Resistant | 4 |
| Week 260 — HU Intolerant | 12 |
Proportion of patients achieving a complete hematological remission at Week 104 as defined by Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104 Endpoint for Week 156, Week 208 and Week 260 were defined, similarly.
| Participants | Ruxolitinib |
|---|---|
| Week 104 | 15 |
| Week 156 | 19 |
| Week 208 | 11 |
| Week 260 | 9 |
Proportion of patients who achieved partial remission at Week 104, based on the ELN and IWG-MRT criteria, as defined by: * MPN-SAF TSS score reduction of greater than or equal to 10 points from baseline to Week 104, and * Hct control defined by the absence of phlebotomy eligibility starting at Week 8 and continuing through Week 104, with no more than one phlebotomy eligibility occurring post-randomization and prior to Week 8, and * WBC \< 10 x10\^9/L at Week 104, and * Platelets ≤ 400 x 10\^9/L at Week 104, and * No palpable spleen at Week 104, and * No hemorrhagic or thrombotic events, and * No transformation into post-PV myelofibrosis, myelodysplastic syndrome (IWG-MRT criteria) or acute leukemia (WHO criteria) Endpoint for Week 156, Week 208 and Week 260 are defined, similarly.
| Participants | Ruxolitinib |
|---|---|
| Week 104 | 4 |
| Week 156 | 9 |
| Week 208 | 4 |
| Week 260 | 0 |
Transformation-free survival is defined as one of the following: 1. Myelofibrosis (MF) as evidenced by bone marrow biopsy, or 2. Acute leukemia as evidenced by bone marrow blast counts of at least 20%, or peripheral blast counts of at least 20% lasting at least 2 weeks. 3. Death due to any cause during treatment period
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants With Transformation Free Survival Events | 4 | 3 |
Overall survival (OS) event is defined as death due to any cause. OS events were counted in the BAT arm, irrespective of whether participants crossed over to receive ruxolitinib when the event occurred.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants With Overall Survival (OS) Events | 3 | 6 |
The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.
| Score on a scale | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 4 | -8.43 ± 12.341 | 0.40 ± 12.586 |
| Week 8 | -9.86 ± 12.210 | 1.37 ± 12.046 |
| Week 16 | -9.14 ± 13.980 | 1.41 ± 10.760 |
| Week 28 | -10.29 ± 14.204 | 2.34 ± 13.047 |
| Week 40 | -9.35 ± 14.027 | 0.10 ± 9.586 |
| Week 52 | -8.63 ± 13.403 | 0.63 ± 9.334 |
| Week 80 | -9.04 ± 13.520 | — |
| Week 92 | -7.69 ± 11.971 | — |
| Week 104 | -6.82 ± 13.297 | — |
| Week 117 | -6.76 ± 13.702 | — |
| Week 130 | -8.26 ± 16.234 | — |
| Week 143 | -8.56 ± 15.653 | — |
| Week 156 | -8.48 ± 15.081 | — |
| Week 169 | -7.65 ± 14.392 | — |
| Week 182 | -9.34 ± 14.675 | — |
| Week 195 | -7.57 ± 14.922 | — |
| Week 208 | -9.26 ± 16.347 | — |
| Week 221 | -7.20 ± 16.054 | — |
| Week 234 | -7.50 ± 15.922 | — |
| Week 247 | -7.82 ± 16.905 | — |
The MPN-SAF TSS is a disease specific questionnaire comprised of 10 items that measures fatigue related to MPN disease and the severity of nine of the most prevalent associated symptoms. Each item is scored on a scale ranging from 0 (no fatigue/absent) to 10 (As bad as you can imagine/worst imaginable).The MPN-SAF TSS is computed as the average of the observed items multiplied by 10 to achieve a 0-to-100 scale. The MPN-SAF TSS thus has a possible score range of 0 to 100 where a decrease indicates improvement.
| Score on a scale | Best Available Therapy (BAT) |
|---|---|
| Week +4 | -8.00 ± 10.532 |
| Week +8 | -9.76 ± 11.543 |
| Week +16 | -9.40 ± 12.040 |
| Week +24 | -9.15 ± 12.738 |
| Week +28 | -8.46 ± 12.212 |
| Week +40 | -8.58 ± 13.302 |
| Week +52 | -7.15 ± 14.392 |
| Week 92 | -10.49 ± 13.902 |
| Week 104 | -8.08 ± 16.288 |
| Week 117 | -9.01 ± 14.708 |
| Week 130 | -10.18 ± 15.740 |
| Week 143 | -8.36 ± 17.030 |
| Week 156 | -9.54 ± 14.573 |
| Week 169 | -11.15 ± 14.305 |
| Week 182 | -10.13 ± 16.113 |
| Week 195 | -10.88 ± 14.357 |
| Week 208 | -9.43 ± 15.360 |
| Week 221 | -10.02 ± 15.986 |
| Week 234 | -8.01 ± 14.404 |
| Week 247 | -9.84 ± 14.979 |
EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.
| Score on a scale | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 4 | 4.24 ± 11.661 | 0.04 ± 18.323 |
| Week 8 | 7.62 ± 14.846 | -2.73 ± 16.097 |
| Week 16 | 6.35 ± 17.946 | -3.12 ± 14.435 |
| Week 28 | 7.56 ± 14.309 | 0.16 ± 15.201 |
| Week 52 | 7.36 ± 13.996 | 2.50 ± 10.697 |
| Week 80 | 4.50 ± 18.273 | — |
| Week 92 | 6.77 ± 18.948 | — |
| Week 104 | 6.25 ± 18.143 | — |
| Week 117 | 6.42 ± 15.130 | — |
| Week 130 | 7.70 ± 16.488 | — |
| Week 143 | 5.68 ± 17.332 | — |
| Week 156 | 4.74 ± 19.032 | — |
| Week 169 | 6.08 ± 18.717 | — |
| Week 182 | 7.68 ± 17.992 | — |
| Week 195 | 6.41 ± 18.239 | — |
| Week 208 | 7.94 ± 18.614 | — |
| Week 221 | 3.64 ± 19.866 | — |
| Week 234 | 5.48 ± 18.625 | — |
| Week 247 | 6.28 ± 17.854 | — |
EQ-5D-5L is a standardized instrument for measuring health outcomes in a wide range of health conditions and treatments. It consists of visual analogue scale (EQ VAS) which records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labeled 'Best imaginable health state' and 'worst imaginable health state'. The EQ VAS scores were anchored on 100 = the best health you can imagine and 0 = worst health you can imagine.
| Score on a scale | Best Available Therapy (BAT) |
|---|---|
| Week +4 | 4.54 ± 14.756 |
| Week +8 | 4.62 ± 15.807 |
| Week +16 | 6.58 ± 14.667 |
| Week +24 | 6.38 ± 17.564 |
| Week +28 | 5.26 ± 15.923 |
| Week +52 | 4.71 ± 21.006 |
| Week 92 | 8.09 ± 16.119 |
| Week 104 | 6.48 ± 18.085 |
| Week 117 | 4.92 ± 16.983 |
| Week 130 | 4.87 ± 20.047 |
| Week 143 | 3.19 ± 17.798 |
| Week 156 | 2.65 ± 20.221 |
| Week 169 | 4.59 ± 13.731 |
| Week 182 | 2.71 ± 19.673 |
| Week 195 | 5.65 ± 18.286 |
| Week 208 | 5.35 ± 18.099 |
| Week 221 | 7.71 ± 16.701 |
| Week 234 | 5.30 ± 18.342 |
| Week 247 | 4.14 ± 16.427 |
The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10
| Percent | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Percent work time missed due to problem (past 7 days) Week 4 | -5.50 ± 18.425 | -0.40 ± 13.928 |
| Percent work time missed due to problem (past 7 days) Week 8 | -4.88 ± 13.381 | -4.35 ± 20.820 |
| Percent work time missed due to problem (past 7 days) Week 16 | 4.50 ± 35.948 | 4.79 ± 25.917 |
| Percent work time missed due to problem (past 7 days) Week 28 | -5.85 ± 17.119 | -2.19 ± 9.852 |
| Percent work time missed due to problem (past 7 days) Week 52 | -2.82 ± 30.770 | -8.33 ± 11.785 |
| Percent work time missed due to problem (past 7 days) Week 80 | 1.87 ± 34.151 | — |
| Percent impairment while working due to problem (past 7 days) Week 4 | -6.67 ± 23.310 | 0.00 ± 14.951 |
| Percent impairment while working due to problem (past 7 days) Week 8 | -13.16 ± 19.164 | -0.59 ± 13.449 |
| Percent impairment while working due to problem (past 7 days) Week 16 | -14.00 ± 21.374 | 4.12 ± 16.977 |
| Percent impairment while working due to problem (past 7 days) Week 28 | -14.29 ± 23.994 | -10.00 ± 14.142 |
| Percent impairment while working due to problem (past 7 days) Week 52 | -10.00 ± 23.170 | -20.00 ± 42.426 |
| Percent impairment while working due to problem (past 7 days) Week 80 | -14.76 ± 26.385 | — |
| Percent overall work impairment due to problem (past 7 days) Week 4 | -9.63 ± 22.495 | -2.34 ± 14.807 |
| Percent overall work impairment due to problem (past 7 days) Week 8 | -11.32 ± 18.505 | -4.38 ± 17.568 |
| Percent overall work impairment due to problem (past 7 days) Week 16 | -10.26 ± 33.296 | 5.34 ± 22.063 |
| Percent overall work impairment due to problem (past 7 days) Week 28 | -15.98 ± 23.077 | -8.85 ± 11.722 |
| Percent overall work impairment due to problem (past 7 days) Week 52 | -12.61 ± 27.576 | -22.50 ± 45.962 |
| Percent overall work impairment due to problem (past 7 days) Week 80 | -14.36 ± 30.691 | — |
| Percent activity impairment due to problem (past 7 days) Week 4 | -11.97 ± 22.122 | 2.42 ± 24.310 |
| Percent activity impairment due to problem (past 7 days) Week 8 | -11.58 ± 24.985 | 1.97 ± 16.413 |
| Percent activity impairment due to problem (past 7 days) Week 16 | -14.36 ± 25.222 | 0.65 ± 18.980 |
| Percent activity impairment due to problem (past 7 days) Week 28 | -11.67 ± 25.826 | 2.73 ± 23.941 |
| Percent activity impairment due to problem (past 7 days) Week 52 | -11.23 ± 25.360 | 0.00 ± 15.374 |
| Percent activity impairment due to problem (past 7 days) Week 80 | -11.09 ± 24.166 | — |
The Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI:SHP) is a six item questionnaire which intended to measure work and activity impairment associated with polycythemia vera. WPAI consisted of 6 questions (Q1=Employment status; Q2=Hours absent from work due to the polycythemia vera; Q3=Hours absent from work due to other reasons; Q4=Hours actually worked; Q5=Impact of the polycythemia vera on productivity while working; Q6=Impact of the polycythemia vera on productivity while doing regular daily activities other than work). Higher WPAI scores indicated greater activity impairment. Scores were multiplied by 100 to express in percentages. Percent work time missed due to problem (past 7 days) =Q2/(Q2+Q4) Percent impairment while working due to problem (past 7 days): Q5/10 Percent overall work impairment due to problem (past 7 says): Q2/(Q2+Q4)+\[(1 Q2/(Q2+Q4))x(Q5/10)\] Percent activity impairment due to problem (past 7 says): Q6/10
| Percent | Best Available Therapy (BAT) |
|---|---|
| Percent work time missed due to problem (past 7 days) Week +4 | -7.45 ± 28.102 |
| Percent work time missed due to problem (past 7 days) Week +8 | -3.90 ± 33.237 |
| Percent work time missed due to problem (past 7 days) Week +16 | -2.66 ± 40.422 |
| Percent work time missed due to problem (past 7 days) Week +24 | -1.67 ± 5.000 |
| Percent work time missed due to problem (past 7 days) Week +28 | 7.06 ± 21.757 |
| Percent work time missed due to problem (past 7 days) Week +52 | 1.12 ± 3.175 |
| Percent impairment while working due to problem (past 7 days) Week +4 | -5.33 ± 9.904 |
| Percent impairment while working due to problem (past 7 days) Week +8 | -4.29 ± 11.579 |
| Percent impairment while working due to problem (past 7 days) Week +16 | -10.83 ± 20.207 |
| Percent impairment while working due to problem (past 7 days) Week +24 | -6.92 ± 13.156 |
| Percent impairment while working due to problem (past 7 days) Week +28 | -3.33 ± 23.868 |
| Percent impairment while working due to problem (past 7 days) Week +52 | -6.00 ± 13.499 |
| Percent overall work impairment due to problem (past 7 days) Week +4 | -10.98 ± 20.249 |
| Percent overall work impairment due to problem (past 7 days) Week +8 | -6.91 ± 24.416 |
| Percent overall work impairment due to problem (past 7 days) Week +16 | -4.73 ± 30.167 |
| Percent overall work impairment due to problem (past 7 days) Week +24 | -6.06 ± 14.099 |
| Percent overall work impairment due to problem (past 7 days) Week +28 | -1.81 ± 20.220 |
| Percent overall work impairment due to problem (past 7 days) Week +52 | -4.03 ± 12.712 |
| Percent activity impairment due to problem (past 7 days) Week +4 | -10.43 ± 19.886 |
| Percent activity impairment due to problem (past 7 days) Week +8 | -8.63 ± 20.978 |
| Percent activity impairment due to problem (past 7 days) Week +16 | -8.82 ± 21.877 |
| Percent activity impairment due to problem (past 7 days) Week +24 | -6.47 ± 25.363 |
| Percent activity impairment due to problem (past 7 days) Week +28 | -6.94 ± 26.395 |
| Percent activity impairment due to problem (past 7 days) Week +52 | -7.00 ± 22.781 |
The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Week 4 — Very much improved | 10 | 0 |
| Week 4 — Much improved | 22 | 8 |
| Week 4 — Minimally improved | 21 | 7 |
| Week 4 — No change | 14 | 50 |
| Week 4 — Minimally worse | 1 | 6 |
| Week 4 — Much worse | 0 | 0 |
| Week 4 — Very much worse | 0 | 1 |
| Week 8 — Very much improved | 11 | 1 |
| Week 8 — Much improved | 27 | 14 |
| Week 8 — Minimally improved | 15 | 9 |
| Week 8 — No change | 15 | 35 |
| Week 8 — Minimally worse | 0 | 10 |
| Week 8 — Much worse | 1 | 0 |
| Week 8 — Very much worse | 0 | 1 |
| Week 16 — Very much improved | 18 | 2 |
| Week 16 — Much improved | 25 | 13 |
| Week 16 — Minimally improved | 13 | 12 |
| Week 16 — No change | 8 | 33 |
| Week 16 — Minimally worse | 2 | 4 |
| Week 16 — Much worse | 0 | 5 |
| Week 16 — Very much worse | 0 | 0 |
| Week 28 — Very much improved | 19 | 0 |
| Week 28 — Much improved | 25 | 4 |
| Week 28 — Minimally improved | 12 | 5 |
| Week 28 — No change | 9 | 15 |
| Week 28 — Minimally worse | 1 | 3 |
| Week 28 — Much worse | 0 | 0 |
| Week 28 — Very much worse | 0 | 0 |
| Week 40 — Very much improved | 23 | 0 |
| Week 40 — Much improved | 30 | 7 |
| Week 40 — Minimally improved | 5 | 2 |
| Week 40 — No change | 6 | 10 |
| Week 40 — Minimally worse | 2 | 0 |
| Week 40 — Much worse | 0 | 0 |
| Week 40 — Very much worse | 0 | 0 |
| Week 52 — Very much improved | 27 | 2 |
| Week 52 — Much improved | 28 | 5 |
| Week 52 — Minimally improved | 8 | 1 |
| Week 52 — No change | 5 | 5 |
| Week 52 — Minimally worse | 2 | 1 |
| Week 52 — Much worse | 0 | 0 |
| Week 52 — Very much worse | 0 | 0 |
| Week 66 — Very much improved | 23 | 1 |
| Week 66 — Much improved | 31 | 1 |
| Week 66 — Minimally improved | 6 | 3 |
| Week 66 — No change | 6 | 0 |
| Week 66 — Minimally worse | 1 | 0 |
| Week 66 — Much worse | 0 | 0 |
| Week 66 — Very much worse | 0 | 0 |
| Week 80 — Very much improved | 22 | 0 |
| Week 80 — Much improved | 24 | 0 |
| Week 80 — Minimally improved | 9 | 0 |
| Week 80 — No change | 10 | 0 |
| Week 80 — Minimally worse | 2 | 0 |
| Week 80 — Much worse | 0 | 0 |
| Week 80 — Very much worse | 1 | 0 |
The Patient Global Impression of Change (PGIC) is comprised of a single question intended to measure a patient's perspective of improvement or deterioration over time relative to treatment. The PGIC uses a seven-point scale where one (1) equals very much improved and seven (7) equals very much worse.
| Participants | Best Available Therapy (BAT) |
|---|---|
| Week +4 — Very much improved | 10 |
| Week +4 — Much improved | 13 |
| Week +4 — Minimally improved | 13 |
| Week +4 — No change | 16 |
| Week +4 — Minimally worse | 0 |
| Week +4 — Much worse | 0 |
| Week +8 — Very much improved | 11 |
| Week +8 — Much improved | 25 |
| Week +8 — Minimally improved | 9 |
| Week +8 — No change | 7 |
| Week +8 — Minimally worse | 1 |
| Week +8 — Much worse | 0 |
| Week +16 — Very much improved | 12 |
| Week +16 — Much improved | 28 |
| Week +16 — Minimally improved | 6 |
| Week +16 — No change | 6 |
| Week +16 — Minimally worse | 0 |
| Week +16 — Much worse | 0 |
| Week +24 — Very much improved | 19 |
| Week +24 — Much improved | 17 |
| Week +24 — Minimally improved | 5 |
| Week +24 — No change | 8 |
| Week +24 — Minimally worse | 1 |
| Week +24 — Much worse | 0 |
| Week +28 — Very much improved | 18 |
| Week +28 — Much improved | 19 |
| Week +28 — Minimally improved | 6 |
| Week +28 — No change | 6 |
| Week +28 — Minimally worse | 1 |
| Week +28 — Much worse | 0 |
| Week +40 — Very much improved | 18 |
| Week +40 — Much improved | 15 |
| Week +40 — Minimally improved | 5 |
| Week +40 — No change | 6 |
| Week +40 — Minimally worse | 0 |
| Week +40 — Much worse | 0 |
| Week +52 — Very much improved | 17 |
| Week +52 — Much improved | 16 |
| Week +52 — Minimally improved | 6 |
| Week +52 — No change | 3 |
| Week +52 — Minimally worse | 0 |
| Week +52 — Much worse | 0 |
Proportion of participants developing any arterial or venous thromboembolic event
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Number of Participants Developing Thrombosis | 0 | 0 |
On-treatment deaths were reported from the day of first dose of study medication to the End of study (End of Treatment +30 days) visit which was Week 260 or prior (+30 days for Rux + crossover) and Week 80 or prior (+30 days for BAT only). Post-treatment deaths were reported following completion study treatment (Week 80 for patients receiving BAT, or Week 260 for patients receiving ruxolitinib) or from the time of premature discontinuation. Patients were followed for survival every three months up to end of study.
| Participants | Ruxolitinib | Best Available Therapy (BAT) |
|---|---|---|
| Death occurring up to 30 days after end of randomised treatment. | 1 | 1 |
| Death occurring among patients who died after cross over to ruxolitinib (BAT arm only). | 0 | 3 |
| Death occurring more than 30 days after end of treatment. | 2 | 2 |
Collected over Adverse events were collected from the day of first dose of study medication to the End of study (End of Treatment +30 days) visit which was Week 260 or prior (+30 days for Rux + crossover) and Week 80 or prior (+30 days for BAT only).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | 1/74 (1.4%) | 34/74 (45.9%) | 73/74 (98.6%) |
| Best Available Therapy | 1/75 (1.3%) | 9/75 (12%) | 56/75 (74.7%) |
| All Crossover Patients | 3/58 (5.2%) | 23/58 (39.7%) | 56/58 (96.6%) |
| Event | Ruxolitinib | Best Available Therapy | All Crossover Patients |
|---|---|---|---|
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 5/74 | 0/75 | 1/58 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/74 | 0/75 | 3/58 |
| BronchitisInfections and infestations | 3/74 | 0/75 | 0/58 |
| Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/74 | 0/75 | 1/58 |
| AstheniaGeneral disorders | 0/74 | 0/75 | 2/58 |
| PneumoniaInfections and infestations | 0/74 | 1/75 | 2/58 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/74 | 0/75 | 2/58 |
| Angina pectorisCardiac disorders | 2/74 | 0/75 | 0/58 |
| Atrial fibrillationCardiac disorders | 2/74 | 1/75 | 1/58 |
| Urinary tract infectionInfections and infestations | 2/74 | 0/75 | 0/58 |
| Event | Ruxolitinib | Best Available Therapy | All Crossover Patients |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 27/74 | 1/75 | 19/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 20/74 | 3/75 | 6/58 |
| Weight increasedInvestigations | 19/74 | 1/75 | 9/58 |
| PruritusSkin and subcutaneous tissue disorders | 12/74 | 17/75 | 7/58 |
| HypertensionVascular disorders | 15/74 | 3/75 | 11/58 |
| ConstipationGastrointestinal disorders | 13/74 | 4/75 | 8/58 |
| FatigueGeneral disorders | 13/74 | 6/75 | 6/58 |
| PyrexiaGeneral disorders | 13/74 | 1/75 | 7/58 |
| HeadacheNervous system disorders | 13/74 | 9/75 | 8/58 |
| NasopharyngitisInfections and infestations | 8/74 | 2/75 | 10/58 |
| Age, Continuous(years) | Ruxolitinib | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Mean | 62.8 ± 11.31 | 66.0 ± 11.12 | 64.4 ± 11.29 |
| Sex: Female, Male(Participants) | Ruxolitinib | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Female | 35 | 28 | 63 |
| Male | 39 | 47 | 86 |
| Race/Ethnicity, Customized(Participants) | Ruxolitinib | Best Available Therapy (BAT) | Total |
|---|---|---|---|
| Caucasian | 67 | 66 | 133 |
| Asian | 4 | 5 | 9 |
| Other | 3 | 4 | 7 |
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Mar 2014 to primary completion in Sep 2015, 18 months.
Results were first posted in Jul 2021, 5 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib